Human trial for pharmacologic ventilator
A new pharmacologic ventilator has shown promising results in a human trial aimed at testing its ability to reverse opioid-induced respiratory depression.
The drug, GAL-021, achieved its aims in a 12-subject test with no safety concerns, according to a trial report published in the journal Anesthesiology, the official journal of the American Society of Anesthesiologists.
GAL-021 acts by blocking potassium channels in the brain that regulate breathing. It has been previously reported that it reverses